Lineage Cell Therapeutics (LCTX) Profit After Tax (2010 - 2026)
Lineage Cell Therapeutics' (LCTX) quarterly Profit After Tax came in at -$4.8 million in Q1 2026, down 15.7% year-on-year from -$5.7 million in Q1 2025, and down 759.64% quarter-over-quarter from $726000.0 in Q4 2025.
Lineage Cell Therapeutics (LCTX) Profit After Tax (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Profit After Tax history runs 17 years deep, the most recent figure standing at -$4.8 million for Q1 2026.
- On a quarterly basis, Profit After Tax fell 15.7% year-over-year to -$4.8 million in Q1 2026; TTM through Mar 2026 was -$64.2 million, a 297.49% decrease from a year earlier, with the FY2025 full-year figure at -$63.5 million, down 241.91% from the prior year.
- Profit After Tax declined to -$4.8 million in Q1 2026 per LCTX's latest filing, from $726000.0 in the prior quarter.
- Across five years, Profit After Tax topped out at $726000.0 in Q4 2025 and bottomed at -$30.4 million in Q2 2025.
- The 5-year median for Profit After Tax is -$5.8 million (2024), against an average of -$7.9 million.
- Biggest YoY gain for Profit After Tax was 122.37% in 2025; the steepest drop was 891.4% in 2025.
- Year by year, Profit After Tax stood at -$6.4 million in 2022, then increased by 24.85% to -$4.8 million in 2023, then surged by 32.02% to -$3.2 million in 2024, then jumped by 122.37% to $726000.0 in 2025, then sank by 759.64% to -$4.8 million in 2026.
- Per Business Quant, the three latest LCTX Profit After Tax figures stand at -$4.8 million (Q1 2026), $726000.0 (Q4 2025), and -$29.8 million (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -36.84 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -65.60 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Lineage Cell Therapeutics | 251.15 Mn | 188.44 Mn | 1.73 Mn | -4.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.79 Mn |
| Dec 31, 2025 | 726,000.00 |
| Sep 30, 2025 | -29.75 Mn |
| Jun 30, 2025 | -30.36 Mn |
| Mar 31, 2025 | -4.14 Mn |
| Dec 31, 2024 | -3.25 Mn |
| Sep 30, 2024 | -3.00 Mn |
| Jun 30, 2024 | -5.76 Mn |
| Mar 31, 2024 | -6.56 Mn |
| Dec 31, 2023 | -4.78 Mn |
| Sep 30, 2023 | -7.16 Mn |
| Jun 30, 2023 | -5.23 Mn |
| Mar 31, 2023 | -4.40 Mn |
| Dec 31, 2022 | -6.35 Mn |
| Sep 30, 2022 | -6.07 Mn |
| Jun 30, 2022 | -6.76 Mn |
| Mar 31, 2022 | -7.09 Mn |
| Dec 31, 2021 | -28.99 Mn |
| Sep 30, 2021 | -7.82 Mn |
| Jun 30, 2021 | -4.79 Mn |